Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02733744 · ClinicalTrials.gov registry record · Early Phase 1
Fecal Microbiota Transplantation After HSCT
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT02733744: Completed Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT02733744 is a Early Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 18 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02733744, a Early Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This research study is studying an intervention called fecal microbiota transplantation (FMT). Patients who are scheduled to undergo Hematopoietic Stem Cell Transplantation are invited to take part in this clinical trial to undergo empiric FMT soon after hematopoietic engraftment. The primary endpoint will be to assess the feasibility of FMT in this population and to assess safety.
Primary Outcome
Number of participants able to ingest 15 FMT capsules over a 2 day period.
Interventions
- BIOLOGICAL Fecal Microbiota Transplantation (FMT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-12 |
| Phase | Early Phase 1 |
What the finished NCT02733744 record still lists
NCT02733744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 1 intervention - of which Fecal Microbiota Transplantation (FMT) is the first listed.
NCT02733744 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02733744 about?
NCT02733744 is a clinical study titled "Fecal Microbiota Transplantation After HSCT". This research study is studying an intervention called fecal microbiota transplantation (FMT). Patients who are scheduled to undergo Hematopoietic Stem Cell Transplantation are invited to take part in this clinical trial to undergo empiric FMT soon after hematopoietic engraftment. The primary endpoi...
What is the current status of trial NCT02733744?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2016-05. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02733744?
The interventions under investigation include: Fecal Microbiota Transplantation (FMT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02733744?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02733744's enrollment target sits among peer trials
18 1316th of 2000 higher than 651 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia